. . "2235-90-7"@en . . . " "@en . . . "illicit"@en . "Alpha-ethyltryptamine"@en . . "investigational"@en . "In the 1960's, alpha-ethyltryptamine (\u03B1ET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. \u03B1ET was an FDA approved antidepressant under the name Monase. However, in 1962, after the discovery of an unacceptable incidence of agranulocytosis, the development of Monase was halted and the drug was withdrawn from potential market use. In 1993, the US Drug Enforcement Administration added \u03B1ET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's. Currently, \u03B1ET is an illegal substance; however, it's activity is still under scientific investigation. \u03B1ET is a stimulant and hallucinogen, but it is less stimulating and hallucinogenic than alpha-methyltryptamine, a closely related compound. Instead, the effects of \u03B1ET, a tryptamine derivative, more closely resemble the amphetamine derived drug 3,4-methylenedioxy-N-methylamphetamine (MDMA). Similarly to MDMA, \u03B1ET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine. Like MDMA, increases in locomotor activity and mood elevation can be seen post administration. "@en . "withdrawn"@en . . . . . . "\u03B1-ET TiHKAL entry \u2022 Isomer Design: http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=11"@en . . . "\u03B1ET"@en . . "The mechanism of action responsible for its antidepressant activity was believed to lie in its ability to inhibit monoamine oxidase, while its stimulant activity on the central nervous system appeared to result from its structural similarity to indole-based psychedelics. [5] Research discovered \u03B1ET to be both a monoamine oxidase inhibitor and a potent monoamine releasing agent capable of serotonergic neurotoxicity. [3] The ability to release serotonin was linked to \u03B1ET's MDMA like properties. [2] \u03B1ET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine. "@en . " "@en . . "Etryptamine"@en . . "Developed in the 1960's for use as an antidepressant before market withdrawal in 1962. "@en . . . "1. Huang, Xuemei, Michael P. Johnson, and David E. Nichols. \"Reduction in brain serotonin markers by \u03B1-ethyltryptamine (Monase).\" European journal of pharmacology 200.1 (1991): 187-190. 2. Krebs, Kirsten M., and Mark A. Geyer. \"Behavioral characterization of alpha-ethyltryptamine, a tryptamine derivative with MDMA-like properties in rats.\" Psychopharmacology 113.2 (1993): 284-287. 3. Martinez, Diana L., and Mark A. Geyer. \"Characterization of the disruptions of prepulse inhibition and habituation of startle induced by \u03B1-ethyltryptamine.\" Neuropsychopharmacology 16.3 (1997): 246-255. 4. Steiner, Wm G., et al. \"\u03B1-Ethyltryptamine (etryptamine): An electroencephalographic, behavioral and neurochemical analysis.\" Psychopharmacology 4.5 (1963): 354-366. 5. \u03B1-ET TiHKAL entry \u2022 Isomer Design: http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=11"@en . . . . . . . "\u03B1-ethyltryptamine"@en . . . . . . . . . . . . . . .